Acne :: A new angle to treat hard-to-reach acne
There is a new angle of attack on body acne in places that are hard-to-reach and treat, such as the back. ClindaReach?, a revolutionary easy to use treatment that packages a topical antibiotic with an ergonomically designed applicator to treat hard-to-reach acne, was launched this week by DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA).
ClindaReach is a prescription product consisting of clindamycin, a frequently prescribed topical antibiotic that is used to treat acne, packaged with a unique EasyReach? applicator to provide an easy and efficient method for treating hard to reach acne.
ClindaReach is initially being introduced to dermatologists in the United States and is now available to pharmacies.
?Until now, individuals were limited in their ability to effectively apply topical medication on hard-to-reach acne afflicted areas of their body, such as the back. My patients end upcontorting their bodies for extended reach, missing areas in need of medication, or relying on another person to help apply it,? commented Mark S.Nestor, M.D., Ph.D. * , clinical associate professor of dermatology and cutaneous surgery, University of Miami, MillerSchool of Medicine, and dermatologic and laser surgeon practicing in Aventura, Florida.
?As with any condition, treatment compliance is essential. When patients find it difficult to maintain a treatment regimen, they stop. ClindaReach is unique because of its simplicity. I love this product!
It takes a proven acne medication, which is packaged with a light-weight wand that makes reaching the entire surface of the back much easier. To me, this is a product we?ve needed for our patients for a very long time.?
Nearly 50 million people in the United States suffer from acne and almost half of those people suffer from back acne.
Bob Doman, DUSA?s President and Chief Operating Officer said, ?We recognized the challenges patients with hard-to-reach acne experience and developed ClindaReach to meet this compelling need. ClindaReach is our first product launch from the pipeline we acquired in our merger with Sirius Laboratories, Inc. in March 2006. We believe that our ability to bring ClindaReach to patients and their physicians underscores both the synergistic opportunities we anticipated with our merger and our commitment to serving patients as a leading provider of dermatological pharmaceuticals through our expanding product portfolio.?